SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001013594-19-000413
Filing Date
2019-06-20
Accepted
2019-06-20 17:29:47
Documents
5

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 3 TO THE SCHEDULE 13D novelion13da3-062019.htm SC 13D/A 89152
2 PETITION novelion993-062019.htm EX-99.3 485
3 PETITION novelion993-062019.pdf EX-99.3 1643038
4 STATEMENT novelion994-062019.htm EX-99.4 486
5 STATEMENT novelion994-062019.pdf EX-99.4 1508307
  Complete submission text file 0001013594-19-000413.txt   4433762
Mailing Address C/O NORTON ROSE FULBRIGHT 1800 - 510 WEST GEORGIA STREET VANCOUVER A1 V6B 0M3
Business Address C/O NORTON ROSE FULBRIGHT 1800 - 510 WEST GEORGIA STREET VANCOUVER A1 V6B 0M3 (877) 764-3131
NOVELION THERAPEUTICS INC. (Subject) CIK: 0000827809 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-43381 | Film No.: 19909336
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O WHITEFORT CAPITAL MANAGEMENT, LP 780 THIRD AVENUE, 26TH FLOOR NEW YORK NY 10017
Business Address C/O WHITEFORT CAPITAL MANAGEMENT, LP 780 THIRD AVENUE, 26TH FLOOR NEW YORK NY 10017 (212) 271-4880
Whitefort Capital Master Fund, LP (Filed by) CIK: 0001704387 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13D/A